FR22C1061I2 - Oligosaccharides comprenant un groupe aminooxy et des conjugues de celui-ci - Google Patents

Oligosaccharides comprenant un groupe aminooxy et des conjugues de celui-ci

Info

Publication number
FR22C1061I2
FR22C1061I2 FR22C1061C FR22C1061C FR22C1061I2 FR 22C1061 I2 FR22C1061 I2 FR 22C1061I2 FR 22C1061 C FR22C1061 C FR 22C1061C FR 22C1061 C FR22C1061 C FR 22C1061C FR 22C1061 I2 FR22C1061 I2 FR 22C1061I2
Authority
FR
France
Prior art keywords
oligosaccharides
conjugates
aminooxy group
aminooxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1061C
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR22C1061I1 publication Critical patent/FR22C1061I1/fr
Application granted granted Critical
Publication of FR22C1061I2 publication Critical patent/FR22C1061I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR22C1061C 2007-01-18 2022-12-15 Oligosaccharides comprenant un groupe aminooxy et des conjugues de celui-ci Active FR22C1061I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88547107P 2007-01-18 2007-01-18
PCT/US2008/051429 WO2008089403A2 (en) 2007-01-18 2008-01-18 Oligosaccharides comprising an aminooxy group and conjugates thereof

Publications (2)

Publication Number Publication Date
FR22C1061I1 FR22C1061I1 (fr) 2023-02-03
FR22C1061I2 true FR22C1061I2 (fr) 2023-11-17

Family

ID=39473250

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1061C Active FR22C1061I2 (fr) 2007-01-18 2022-12-15 Oligosaccharides comprenant un groupe aminooxy et des conjugues de celui-ci

Country Status (19)

Country Link
US (5) US8759501B2 (ja)
EP (5) EP2121713B1 (ja)
JP (6) JP5999867B2 (ja)
CN (2) CN101631794B (ja)
CA (1) CA2675968C (ja)
CY (2) CY1119954T1 (ja)
DK (3) DK2457919T3 (ja)
ES (3) ES2744574T3 (ja)
FR (1) FR22C1061I2 (ja)
HR (3) HRP20130744T1 (ja)
HU (3) HUE045046T2 (ja)
IL (3) IL243117B2 (ja)
LT (2) LT2457920T (ja)
NL (1) NL301210I2 (ja)
NO (2) NO2457920T3 (ja)
PL (3) PL2457920T3 (ja)
PT (3) PT2457920T (ja)
SI (2) SI2457920T1 (ja)
WO (1) WO2008089403A2 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US8795680B2 (en) * 2006-07-21 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2009024977A2 (en) * 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
PL2465542T3 (pl) * 2008-12-16 2015-06-30 Genzyme Corp Koniugaty białko-oligosacharyd
EP2448600B1 (en) 2009-07-03 2016-03-30 INSERM - Institut National de la Santé et de la Recherche Médicale Compounds targeting the cation-independent mannose 6-phosphate receptor
CN104530182A (zh) * 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011163568A1 (en) * 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
WO2012082635A1 (en) * 2010-12-13 2012-06-21 Ancora Pharmaceuticals, Inc. Synthetic oligosaccharide group a streptococcus
JP5913372B2 (ja) 2011-01-20 2016-04-27 プロタリクス リミテッド 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物
CA2901978A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
TWI821227B (zh) 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
AU2019377869A1 (en) * 2018-11-08 2021-05-27 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof
EP4100064A1 (en) 2020-02-07 2022-12-14 Novartis AG Targeted plasma protein degradation
JP2023512783A (ja) 2020-02-08 2023-03-29 ジェンザイム・コーポレーション ポンペ病を処置するための組成物および方法
EP4164678A1 (en) 2020-06-14 2023-04-19 Genzyme Corporation Compositions and methods for treating late-onset pompe disease

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2940845B1 (de) 1979-10-09 1980-06-26 Ford Werke Ag Kreiselpumpendichtung,insbesondere fuer Kuehlwasserpumpen in Kraftfahrzeugen
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5212298A (en) * 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) * 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5583042A (en) * 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0513332A4 (en) * 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
AU1580292A (en) * 1991-03-13 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPO190596A0 (en) * 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
ES2335557T3 (es) * 1997-01-21 2010-03-29 Sanofi Pasteur Conjugados de peptido-polisacarido.
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
DE69835367T2 (de) 1997-10-29 2007-08-02 Genzyme Corp., Framingham Gentherapie für gaucher-krankheit
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6538117B1 (en) * 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
WO2000010599A2 (en) * 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
EP1183230A1 (en) * 1999-06-08 2002-03-06 La Jolla Pharmaceutical Valency platform molecules comprising aminooxy groups
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001238346A1 (en) 2000-02-15 2001-08-27 Genzyme Corporation Modification of biopolymers for improved drug delivery
US20040067527A1 (en) 2000-07-26 2004-04-08 Sara Lavi Intracellular delivery system for protein phosphatases and other polypeptides
DE60110094T2 (de) * 2000-08-18 2009-10-01 Massachusetts Institute Of Technology, Cambridge Vorrichtung und verfahren zur automatisierten synthese von oligosacchariden
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
AU2001260526A1 (en) 2001-05-07 2001-12-03 Supratek Pharma, Inc. A ligand for enhancing oral and cns delivery of biological agents
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ES2516041T3 (es) 2001-10-10 2014-10-30 Ratiopharm Gmbh Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
TWI295483B (en) 2002-01-31 2008-04-01 Sumitomo Chemical Co 3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same
ATE441706T1 (de) * 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
KR101270692B1 (ko) 2003-08-12 2013-06-03 리폭센 테크놀로지즈 리미티드 폴리시알산 유도체
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
EP1713508A2 (en) 2004-01-29 2006-10-25 Biosynexus Incorporated Use of amino-oxy functional groups in the preparation of vaccine conjugates
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
PL2465542T3 (pl) * 2008-12-16 2015-06-30 Genzyme Corp Koniugaty białko-oligosacharyd

Also Published As

Publication number Publication date
FR22C1061I1 (fr) 2023-02-03
NL301210I2 (nl) 2023-02-02
ES2417146T3 (es) 2013-08-06
PT2457919T (pt) 2019-09-20
US10907142B2 (en) 2021-02-02
US20170014520A1 (en) 2017-01-19
SI2457920T1 (en) 2018-02-28
WO2008089403A2 (en) 2008-07-24
LT2457919T (lt) 2019-09-25
CY1119954T1 (el) 2018-12-12
EP2457920A1 (en) 2012-05-30
CY1122452T1 (el) 2021-01-27
JP2017052962A (ja) 2017-03-16
US20200010825A1 (en) 2020-01-09
NO2022056I1 (no) 2022-12-09
US20220204963A1 (en) 2022-06-30
US8759501B2 (en) 2014-06-24
WO2008089403A3 (en) 2008-11-13
PL2121713T3 (pl) 2013-11-29
JP2022137232A (ja) 2022-09-21
IL199925A (en) 2017-09-28
DK2121713T3 (da) 2013-06-24
ES2656314T3 (es) 2018-02-26
SI2457919T1 (sl) 2019-10-30
EP2457919A1 (en) 2012-05-30
JP2015078360A (ja) 2015-04-23
EP2121713B1 (en) 2013-06-12
CN101631794B (zh) 2013-01-02
PL2457920T3 (pl) 2018-03-30
EP2457920B1 (en) 2017-10-25
CA2675968A1 (en) 2008-07-24
EP3597655B1 (en) 2023-08-02
ES2744574T3 (es) 2020-02-25
EP4293112A3 (en) 2024-03-13
HUS2200055I1 (hu) 2023-01-28
EP2457919B1 (en) 2019-06-05
IL222792A0 (en) 2012-12-31
JP5999867B2 (ja) 2016-09-28
JP6039625B2 (ja) 2016-12-07
IL243117B (en) 2022-11-01
CN101631794A (zh) 2010-01-20
HRP20180076T1 (hr) 2018-02-23
LT2457920T (lt) 2018-02-12
HUE036140T2 (hu) 2018-06-28
IL243117A (ja) 2016-01-31
EP4293112A2 (en) 2023-12-20
HRP20191562T1 (hr) 2019-11-29
PL2457919T3 (pl) 2019-12-31
PT2457920T (pt) 2018-01-23
CN102978185B (zh) 2015-02-11
IL243117B2 (en) 2023-03-01
HUE045046T2 (hu) 2019-12-30
PT2121713E (pt) 2013-06-25
US20150050262A1 (en) 2015-02-19
HRP20130744T1 (hr) 2013-10-11
CA2675968C (en) 2019-05-21
US20100047225A1 (en) 2010-02-25
JP2010516257A (ja) 2010-05-20
NL301210I1 (nl) 2022-12-21
CN102978185A (zh) 2013-03-20
EP3597655A1 (en) 2020-01-22
US9469850B2 (en) 2016-10-18
JP6309592B2 (ja) 2018-04-11
EP2121713A2 (en) 2009-11-25
JP2018109194A (ja) 2018-07-12
JP2020185011A (ja) 2020-11-19
DK2457919T3 (da) 2019-09-16
IL199925A0 (en) 2010-04-15
NO2457920T3 (ja) 2018-03-24
DK2457920T3 (en) 2018-01-22

Similar Documents

Publication Publication Date Title
FR22C1061I2 (fr) Oligosaccharides comprenant un groupe aminooxy et des conjugues de celui-ci
BRPI0923473A2 (pt) dispositivo de cigarro simulado, e, sistema
DK1973564T3 (da) Vaccine omfattende streptococcus pneumoniae-kapselpolysaccharidkonjugat
DK2444807T3 (da) Mono- og dinitropyrazolhaptenkonjugater
DK3207941T6 (da) Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater
ZA200802225B (en) Interleukin-1 conjugates and uses thereof
ZA201001206B (en) Saccharide-containing protein conjugates and uses thereof
FR2944571B1 (fr) Ensemble de support antichoc et detecteur comprenant celui-ci
DE602007011305D1 (de) Kaffee- und teedosiersystem
TWI349428B (en) Class ab amplifier
GB0515122D0 (en) Intolerance testing device and system
DE112008001073A5 (de) Begasungsvorrichtung und -system
ITMI20080183A1 (it) Dispositivo amplificatore e sistema impiegante il dispositivo
GB0701081D0 (en) Intolerance testing device and system
SI2121713T1 (sl) Oligosaharidi, ki obsegajo aminooksi skupino, in njihovi konjugati
FR2916702B1 (fr) Console nomade et escamotable.
BRPI0912444A2 (pt) "arranjo de fixação, parte da parede e unidade de conexão"
NL1034526A1 (nl) Emoticoninrichting.
FR2912170B1 (fr) Isoloir demontable et modulable.
NL1033481A1 (nl) Tooninrichting en werkwijzen.
ES1061833Y (es) Aparato de pedaleo estatico transformable en butaca.
ITMO20050146A1 (it) Dispositivo amplificatore.
NL1034157A1 (nl) Sterilisatie-inrichting.
CL2007002339S1 (es) Aparato desodorizador.
CL2008000476S1 (es) Aparato desodorizador.